• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Upexi Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/20/25 6:02:50 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    8-K 1 upxi_8k.htm FORM 8-K upxi_8k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): June 16, 2025

     

    UPEXI, INC.

    (Exact name of registrant as specified in its charter)

     

    Nevada

    333-25526

    83-3378978

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification Number)

     

    3030 N. Rocky Point Drive, Suite 420

    Tampa, FL 33607

    (Address of principal executive offices)

     

    (701) 353-5425

    (Registrant’s telephone number, including area code)

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 16, 2025, Upexi, Inc. (the “Company”) (NASDAQ: UPXI) held its 2025 Annual Meeting of stockholders. The following matters were considered:

     

    1. Election of Directors

     

    Stockholders elected all of the Company’s nominees for director for one-year terms expiring on the next annual meeting of stockholders. The voting results were as follows:

     

     

     

     

    For

     

     

    Against

     

     

    Withheld

     

    (1) Mr. Allan Marshall

     

     

    1,800,047

     

     

     

    -

     

     

     

    54,498

     

    (2) Mr. Andrew Norstrud

     

     

    1,832,266

     

     

     

    -

     

     

     

    22,279

     

    (3) Mr. Gene Salkind

     

     

    1,817,737

     

     

     

    -

     

     

     

    36,808

     

    (4) Mr. Thomas Williams

     

     

    1,816,800

     

     

     

    -

     

     

     

    37,745

     

    (5) Mr. Lawrence Dugan

     

     

    1,817,625

     

     

     

    -

     

     

     

    36,920

     

     

    2. Approve Re-Domiciling of the Company as a Delaware Corporation

     

    Stockholders approved the re-domiciling of the Company as a Delaware Corporation. The voting results were as follows:

     

    For

     

    Against

     

    Abstained/Withheld

     

    Broker Non-Vote

    1,835,223

     

    2,150

    17,172

    301,423

     

    3. Increase in Number of Shares to Stock Option Plan

     

    Stockholders approved an increase in the number of shares to the Company’s Stock Option Plan to 10,000,000 shares. The voting results were as follows:

     

    For

     

    Against

     

    Abstained/Withheld

     

    Broker Non-Vote

    1,780,880

     

    73,501

    164

    301,423

     

    4. Advisory Vote on Executive Compensation

     

    Stockholders approved the advisory vote on the compensation of the Company’s named executive officers. The voting results were as follows:

     

    For

     

    Against

     

    Abstained/Withheld

     

    Broker Non-Vote

    1,784,871

     

    69,408

    266

    301,423

     

    5. Advisory Vote on Frequency of Advisory Vote on Executive Compensation

     

    Stockholders approved, on a non-binding, advisory basis, the frequency of 3 years for future advisory votes on the compensation of the Company’s named executive officers. The voting results were as follows:

     

    1 Year

     

    2 Years

     

    3 Years

     

    Abstain

    191,206

     

    1,425

    1,659,927

    1,987

     

    6. Ratify GBQ Partners LLC as Independent Registered Public Accountant

     

    Stockholders approved and ratified the appointment of GBQ Partners LLC to serve as the Company’s independent registered public accounting firm for the fiscal year 2025. The voting results were as follows:

     

    For

     

    Against

     

    Abstained/Withheld

     

    Broker Non-Vote

    2,109,084

     

    45,622

    1,262

    -

     

     
    2

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    UPEXI, INC.

     

     

     

     

     

    Date: June 19, 2025

    By:

    /s/ Andrew Norstrud

     

     

     

    Andrew Norstrud

     

     

     

    Chief Financial Officer

     

     
    3

     

    Get the next $UPXI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Rudick Brian Benjamin claimed ownership of 438,597 shares (SEC Form 3)

      3 - UPEXI, INC. (0001775194) (Issuer)

      6/3/25 6:04:17 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Williams Thomas Charles

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:45 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    SEC Filings

    See more
    • Upexi Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - UPEXI, INC. (0001775194) (Filer)

      6/26/25 5:00:22 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Upexi Inc.

      EFFECT - UPEXI, INC. (0001775194) (Filer)

      6/24/25 12:15:14 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B3 filed by Upexi Inc.

      424B3 - UPEXI, INC. (0001775194) (Filer)

      6/23/25 5:00:28 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Marshall Allan bought $1,500,001 worth of shares (657,895 units at $2.28) and was granted 75,000 shares, increasing direct ownership by 484% to 884,318 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:36 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Norstrud Andrew James bought $100,001 worth of shares (43,860 units at $2.28) and was granted 100,000 shares, increasing direct ownership by 942% to 159,138 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:26 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Salkind Gene bought $550,002 worth of shares (241,229 units at $2.28), increasing direct ownership by 195% to 365,127 units (SEC Form 4)

      4 - UPEXI, INC. (0001775194) (Issuer)

      4/25/25 4:01:17 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Upexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening Bell

      TAMPA, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced its intention to tokenize its SEC-registered shares using Opening Bell, an on-chain issuance platform from financial technology firm Superstate. Opening Bell enables companies to tokenize public equity via blockchain infrastructure, making shares tradable on-chain. This announcement expands upon Upexi's existing Nasdaq listing and upon official listing may introduce key investor benefits, including: 24/7 trading and

      6/26/25 8:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Nakamoto Holdings to Participate in ICR Conference Spotlight Series

      Nakamoto Holdings Inc. ("Nakamoto"), a Bitcoin-native holding that has entered into a definitive merger agreement with KindlyMD, Inc. (NASDAQ:NAKA) ("KindlyMD"), is pleased to share that David Bailey, Chief Executive Officer, will participate in an ICR Conference Spotlight Series webinar taking place on Friday, June 20, 2025 at 11am ET. The webinar, titled "HODL On Tight: Examining The Rise of Public Market Crypto Balance Sheet Strategies", will examine the evolution of crypto balance sheet strategies and the strategic rationale and benefits driving the proliferation of these public market companies. David will be joined by executives from Clear Street Investment Banking, Upexi, Inc. (NAS

      6/17/25 4:05:00 PM ET
      $NAKA
      $UPXI
      Medical/Nursing Services
      Health Care
      Medicinal Chemicals and Botanical Products
    • Upexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20th

      TAMPA, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced that Brian Rudick, CFA, Chief Strategy Officer (CSO), will present on a panel at the ICR Conference Spotlight Series on Friday, June 20, 2025, at 11:00 a.m. ET. Along with Upexi's CSO Brian Rudick, this virtual panel will feature industry leaders including David Bailey, Founder and CEO of Nakamoto, Leah Wald, President & Chief Executive Officer at Sol Strategies, Inc., and John D'Agostini, Co-Head of Investment Banking at Cl

      6/17/25 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

      6/16/25 7:42:40 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Financials

    Live finance-specific insights

    See more
    • Upexi Regains Compliance with NASDAQ

      Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

      12/23/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi Reports Fiscal Second Quarter 2024 Financial Results

      TAMPA, FL / ACCESSWIRE / February 14, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct to Consumer brand owner and innovator in aggregation, today reported its financial results for the fiscal second quarter 2024 ending December 31, 2023."During the quarter we continued to focus on optimizing and streamlining our operations, investing in our higher margin Brand Products and generating positive Adjusted EBITDA. While revenue for the most recent fiscal second quarter decreased sequentially, the operating measures we took allowed us to increase gross profit margins to 38%, as compared to the prior fiscal first quarter of 31.8%. We also generated pos

      2/14/24 4:05:00 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET

      TAMPA, FL / ACCESSWIRE / February 12, 2024 / Upexi Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a multi-faceted Amazon and Direct-to-Consumer brand owner and innovator in aggregation, today announced it will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. ET, to discuss its financial results for the fiscal 2024 second quarter and provide a business update.Financial Results Conference CallEvent:Fiscal 2024 Second Quarter Financial Results Conference CallDate:Wednesday, February 14, 2024Time:4:30 p.m. Eastern TimeLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://ir.upexi.com/news-events/ir-calendarFor those unable to join the confe

      2/12/24 9:00:00 AM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      5/31/23 7:05:10 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Upexi Inc.

      SC 13G - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:37:37 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

      SC 13G/A - UPEXI, INC. (0001775194) (Subject)

      3/10/23 4:36:56 PM ET
      $UPXI
      Medicinal Chemicals and Botanical Products
      Health Care